BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 34625994)

  • 1. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
    Hallek M; Al-Sawaf O
    Am J Hematol; 2021 Dec; 96(12):1679-1705. PubMed ID: 34625994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2013 Sep; 88(9):803-16. PubMed ID: 23720127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
    Shadman M
    JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First line therapy of CLL.
    Hallek M
    Hematol Oncol; 2023 Jun; 41 Suppl 1():129-135. PubMed ID: 37294974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic markers and standard management of chronic lymphocytic leukemia.
    Stilgenbauer S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.
    Burke JM
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):427-435. PubMed ID: 35577753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
    Islam P
    Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial therapy of chronic lymphocytic leukemia.
    Eichhorst B; Cramer P; Hallek M
    Semin Oncol; 2016 Apr; 43(2):241-50. PubMed ID: 27040702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.
    Wiedmeier-Nutor J; Leis J
    Curr Treat Options Oncol; 2022 Jun; 23(6):904-919. PubMed ID: 35435617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
    Lama TG; Kyung D; O'Brien S
    Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
    Odetola O; Ma S
    Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
    Iovino L; Shadman M
    Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of chronic lymphocytic leukemia.
    Stilgenbauer S; Furman RR; Zent CS
    Am Soc Clin Oncol Educ Book; 2015; ():164-75. PubMed ID: 25993154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.